- Press Releases
- Notices
Press Releases To List
-
- Apr.24.2025R & D
- Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
- Apr.21.2025Licensing
- Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics
-
- Apr.18.2025Sustainability
- ONO Achieves Top 1% in S&P Sustainability Yearbook 2025
-
- Apr.14.2025R & D
- U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
-
- Apr.11.2025R & D
- U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer
Notices To List
-
- Mar.14.2025Corporate
- Notice about the Establishment of the ONO PHARMA Heritage Center
-
- Mar.10.2025Corporate
- Notice about Posting of the Sustainability Meeting Script
-
- Oct.01.2024Corporate
- ONO begins Airing New Commercial “Rising to the challenges of Immuno-Oncology” in Japan
-
- Sep.30.2024Corporate
- Corporate Report 2024 has been released.
-
- Jun.21.2024Corporate
- Voting Results (Extraordinary Report) of the 76th Ordinary General Shareholders’ Meeting
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
